Medication Adherence in Patients with High LDL Cholesterol

Author(s):

Pam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC

The panel explores issues surrounding medication adherence and the potential for improved patient engagement. They emphasize that poor medication adherence increases the risk of cardiovascular events and discuss factors such as drug cost, timing of administration, and the importance of adopting a patient-centric approach to optimize treatment success.

EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management

EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients

EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment

EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy

EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

EP: 6.Evaluating Safety of Novel LDL Management Mechanism

EP: 7.Examining Results from VICTORION-INITIATE Trial

EP: 8.Other Notable Emerging Lipid-Lowering Treatments

EP: 9.REDUCE-IT Trial and Triglyceride-Lowering Agents

EP: 10.Diabetes, GLP-1, and Lipid Reduction

Now Viewing

EP: 11.Medication Adherence in Patients with High LDL Cholesterol

EP: 12.Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

EP: 13.Cardiometabolic Medicine: Seeing the Patient as a Whole

Video content above is prompted by the following questions:

Adherence remains a big hurdle in lipid management. A well-known rule in medicine is, “the more educated the patient, the more adherent the patient.”
- How do you implement patient education on cardiovascular health into your practice? What are persistent gaps?
- How are the novel molecular treatments affecting adherence to lipid lowering therapies? (examples from your practice?)
- What is still needed on a larger/national scale to educate patients as well as providers on the importance of lipid screening and the availability of safe and effective medication?